Answers are grounded in this paper and cite their sources.
Somatic genome editing may provide durable treatment for selected cardiovascular diseases, but its translational maturity is organ-dependent. This narrative review compares CRISPR-Cas nucleases, base editors, and prime editors across liver-directed and direct myocardial applications, with emphasis on target biology, delivery, genomic integrity, clinical evidence, and long-term governance. Liver-directed editing of PCSK9, ANGPTL3, and TTR has produced sustained pharmacodynamic effects after one administration in early clinical studies; these findings establish target engagement, not yet reductions in cardiovascular events, reversal of amyloid cardiomyopathy, or lifelong safety. Direct myocardial editing remains preclinical. MYH7 and MYBPC3 studies demonstrate variant-specific disease prevention in selected neonatal or presymptomatic models, but do not establish reversal of mature hypertrophy, fibrosis, dysfunction, or arrhythmia in adult human myocardium. The principal translational divide therefore reflects the convergence of validated target direction, accessible delivery, measurable systemic output, and tolerable editing heterogeneity in the liver, versus the need for allele-selective, spatially distributed correction in an electrically and mechanically coupled heart. We propose an organ-specific translational evidence framework that separates evidence required before first-in-human administration from evidence generated during clinical development. Progress will depend on clinically meaningful outcomes, cell- and region-resolved editing, product-specific genomic safety, credible management of persistent harm, and durable surveillance.
No takes yet. Share an insight, caveat, or question.
Khawli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: